In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Desmopressin | Synthetic analog Melanotan I (afamelanotide) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 695 | 667 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 86 (81 in people) | 36 (29 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 102 · 14 active19 more mention it but do not test it | 23 · 1 active | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Ddavp says: “Antidiuretic replacement in central diabetes insipidus, temporary polyuria and polydipsia after head trauma or pituitary-region surgery, and primary nocturnal enuresis”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Desmopressin | Melanotan I (afamelanotide) |
|---|---|---|
| Adverse eventsWhole body | 73721 | 29245 |
| Receptor activity and mechanism |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Scenesse says: “Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)”
1037 |
231521781 |
| Skin and hairSkin and wound | 11 | 27252 |
|---|
| PharmacokineticsPharmacology | 22814 | 10631 |
|---|
| Quality of lifeWhole body | 44 | 1414 |
|---|
| PainWhole body | 99 | 752 |
|---|
| SleepSleep | 1313 | 11 |
|---|
| Kidney functionKidney and urinary | 18117 | 21165 |
|---|
| Hormone levelsEndocrine and hormones | 77 | 431 |
|---|
| Treatment adherence and retentionWhole body | 66 | 44 |
|---|
| Blood pressureCardiovascular | 77 | 33 |
|---|
| Cognition and memoryNervous system and cognition | 77 | 33 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Melanotan I (afamelanotide) differs from Alpha-melanocyte-stimulating hormone (alpha-MSH) at 2 positions and carries 2 added groups.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 102 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ferring Pharmaceuticals799 participantsMay 2007 to Feb 2008
Nocturia
Ferring Pharmaceuticals554 participantsDec 2007 to May 2010
Nocturia
Ferring Pharmaceuticals395 participantsFeb 2011 to Jan 2012
Nocturia
19 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 23 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Clinuvel Pharmaceuticals Limited100 participantsMay 2007 to 9 Dec 2009
Erythropoietic Protoporphyria
Clinuvel Pharmaceuticals Limited93 participantsMay 2012 to Jul 2013
Erythropoietic Protoporphyria
Clinuvel Pharmaceuticals Limited74 participantsSept 2009 to May 2011
Erythropoietic Protoporphyria
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Desmopressin | Melanotan I (afamelanotide) |
|---|---|---|
| Treatment adherence and retentionKidney and urinaryCompared as: value in the arm that got the peptide, in children | 4 children Withdrawals 6 monthsn = 1422015 | No randomized trial result 4 results from other study designs. |
| Blood pressureCardiovascularCompared as: difference from placebo, in p | 0.28 P P value, standing blood pressure DDAVP versus placebo Dose studied: 0.2 mgn = 302012 | No randomized trial result 3 results from other study designs. |
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in beats/min | 101.9 beats/min Standing heart rate · after DDAVP 0.2 mg (SD 14.5) After placebo (SD 17.4): 109.2 beats/min Dose studied: 0.2 mgn = 302012 | No randomized trial result 6 results from other study designs. |
| Receptor activity and mechanismCardiovascularCompared as: value in the arm that got the peptide, in %.h | 4667 %.h von Willebrand Factor antigen GLS mean AUEC Dose studied: 0·3 μg/kgn = 212014 | No randomized trial result 231 results from other study designs. |
| PainKidney and urinaryCompared as: value in the arm that got the peptide, in vas score | 5 VAS score Mean pain Dose studied: 40 microgn not reported2001 | No randomized trial result 7 results from other study designs. |
| SleepSleepCompared as: difference from placebo, in min | ≈ 40 min Increase in time to first void from baseline Dose studied: 50 μg3 monthsn not reported2013 | |
| Adverse eventsInfectionCompared as: value in the arm that got the peptide, in % | 17% Adverse events Placebo: 25% Dose studied: 0.1, 0.2 or 0.4 mg3 weeksn = 1512002 |
4 children
Withdrawals
6 monthsn = 1422015
No randomized trial result
4 results from other study designs.
No randomized trial result
1 result from other study designs.
No comparable result
7 randomized-trial results measure it in another way or another unit.
0.28 P
P value, standing blood pressure DDAVP versus placebo
Dose studied: 0.2 mgn = 302012
No randomized trial result
3 results from other study designs.
101.9 beats/min
Standing heart rate · after DDAVP 0.2 mg (SD 14.5)
After placebo (SD 17.4): 109.2 beats/min
Dose studied: 0.2 mgn = 302012
No randomized trial result
6 results from other study designs.
4667 %.h
von Willebrand Factor antigen GLS mean AUEC
Dose studied: 0·3 μg/kgn = 212014
No randomized trial result
231 results from other study designs.
5 VAS score
Mean pain
Dose studied: 40 microgn not reported2001
No randomized trial result
7 results from other study designs.
≈ 40 min
Increase in time to first void from baseline
Dose studied: 50 μg3 monthsn not reported2013
No randomized trial result
1 result from other study designs.
17%
Adverse events
Placebo: 25%
Dose studied: 0.1, 0.2 or 0.4 mg3 weeksn = 1512002
No comparable result
7 randomized-trial results measure it in another way or another unit.